PubMed Health⌕ Search

Biomedical subjects

L Mignot

Publications and source records attributed to L Mignot.

At least 55 records · Page 3Linked to original sources
PubMed1987

[Value of initial chemotherapy in the treatment of advanced cancers of the uterine cervix].

Eleven patients who had advanced cancer of the cervix were treated with combination chemotherapy containing Cisplatin as a primary treatment. The cases were: 3 stage II B N+, 2 stage III not involving the bladder, 3 stage III involving the bladder and 3 stage IV. The response rate was 40% with 6 patients responding. The response was better than 50% in 3 and there were 5 failures. In the 6 patients where the treatment was helpful, 2 could have extended surgery whereas the others had follow-up radiotherapy without developing urinary fistulae. Just as it to be found in the literature, it was not possible to pick out prognostic criteria for sensitivity to chemotherapy. A protocol for treatment is suggested, starting with a therapeutic test of chemotherapy. If this is successful it should be followed by extended surgery or radiotherapy. It if is not successful, conventional treatment with radiotherapy will be undertaken. It is essential to carry out multicentre studies in future to find out whether this attitude is going to be successful.

Adult↗
PubMed1987

[Importance of anthracyclines in tumors of the ovary and endometrium and soft tissue sarcomas].

Anthracyclines, especially Adriamycin stand as a major progress in cancer chemotherapy: in ovarian carcinoma anthracyclines are combined to cyclophosphamide and cisplatin to obtain a rapid and complete remission; in endometrial carcinoma Adriamycin is the most active drug for palliative treatment; in soft-tissue sarcomas, anthracyclines in combination with other drugs give 15 to 65% response rates (8 months of median duration) in metastatic situation; except in one study (NCl), all adjuvant studies with these drugs are actually negative.

Antibiotics, Antineoplastic↗
PubMed1986

[Pregnancy after treated breast cancer. Results of a case-control study].

Sixty-eight cases of pregnancy after carcinoma of the breast were collected during a survey conducted by the Société Française de Gynécologie: 27 patients had one or several pregnancies interrupted at an early stage; 41 patients had at least one uninterrupted pregnancy. The fate of these patients was compared to that of 136 controls similar in all respects, except for the absence of post-cancer pregnancy. There was no significant difference in survival curves: the 10-year survival rate in our 68 patients was 71% (90% in those with N- cancer; 71% in those with N+ cancer, with no significant difference between cases and controls in each group). The patients whose pregnancies were interrupted had the same prognosis as those who delivered at term. The survival of 14 patients who conceived within 6 months of the breast cancer treatment was not significantly different from that of the corresponding controls. Pregnancy after breast cancer does not seem to alter the prognosis of the disease. In women with good prognosis cancer, the survival rate is excellent whatever the delay between cancer and pregnancy, and women should not be discouraged from having children; in women with poor prognosis cancer (N+), the outcome is not modified by pregnancy, and it remains lethal in about 50% of cases.

Adult↗
PubMed1985

[Role of chemotherapy in the treatment of cancer of the testis in adults].

Owing to its considerable effectiveness, modern multiple chemotherapy ranks first in the treatment of non-seminoma metastatic tumours of the testis. Its side-effects in short-term treatment are recognized and acceptable in view of the results obtained, but they remain imperfectly known in long-term treatments. Fort this reason, the present tendency in clinical stage I non-seminoma tumours is to reserve chemotherapy for patients who relapsed after orchidectomy. Advanced seminomas with or without high levels of human chorionic gonadotrophin (subunit beta) already benefit from chemotherapy, and this treatment is likely to be extended to less disseminated forms of cancer. Pure or predominant choriocarcinomas still respond poorly to the cytotoxic drugs at present available.

Adult↗
PubMed1983

Fluorouracil (F), Adriamycin (A), and cisplatin (P) (FAP): combination chemotherapy of advanced esophageal carcinoma.

Twenty-one patients with advanced epidermoid carcinoma of the esophagus were treated with a combination of 5-fluorouracil (F) 600 mg/m2 day 1 and day 8; Adriamycin (A) 30 mg/m2 day 1; and cisplatin (P) 75 mg/m2 day 1 (FAP) with hydration and mannitol-induced diuresis. Each course was repeated every 4 weeks. All 21 patients are evaluable for response: 7 patients had an objective response (33%). Two of these responses were complete remissions according to negative endoscopic and pathologic results; five patients had a partial response; all 7 responding patients had metastasis prior to treatment. Median survival of the 21 patients was 8 months. Median survival of 9 months for responders is superior to 4.5 months for nonresponders. No severe myelosuppression or nephrotoxicity was observed. This FAP regimen is useful in the treatment of advanced esophageal tumors.

Adult↗
PubMed1983

[Hormone receptors and precancerous lesions of the breast].

Little attention has been given to hormone receptors in preinvasive breast lesions. Results of biochemical analyses of duct in situ carcinomas reveal hormone receptors presence but with lower levels than in infiltrative lesions. Histochemical methods applied for lobular in situ carcinomas are not specific. The data would seem to warrant an investigation of the possible use of hormonal treatment in alternative of preventive surgery usually applied in preinvasive lesions.

Breast Neoplasms↗
PubMed1982

[Treatment of advanced epidermoid carcinoma of the oesophagus with combined 5-fluorouracil, adriamycin and cis-platinum (FAP)].

Twenty-one patients with advanced, inoperable epidermoid carcinoma of the oesophagus were treated with combined 5-fluorouracil (F, 600 mg/m2, days 1 and 8), adriamycin (A, 30 mg/m2, day 1) and cis-platinum (C, 75 mg/m2, day 1), together with hydratation and mannitol-induced diuresis. Each course was repeated after 4 weeks. Response could be assessed in all 21 patients and was objective in seven (33%), who had metastasis prior to treatment. Two of these 7 patients went into complete remission confirmed by negative endoscopy and pathology; 5 showed partial response. Median survival of the 21 patients was 8 months; it fell to 4.5 months in non-responders and rose over 9 months in responders. Three patients survived for more than 16 months. No severe bone marrow depression or nephrotoxicity was observed. The 3-drug combination appeared to be more effective than the additive effects of each drug given separately. It is concluded that the FAP regimen is useful in the treatment of advanced oesophageal tumours.

Adult↗
PubMed1982

[Prevention of chemotherapy-induced alopecia in cancer patients by scalp hypothermia (author's transl)].

Chemotherapy-induced alopecia observed in cancer patients can now be prevented by a simple, effective, inexpensive and well tolerated procedure: scalp hypothermia. Refrigeration is obtained by placing on the scalp two bags filled with crushed ice 15 minutes before, and removing them 15 minutes after intravenous injection of antineoplastic drugs. Only patients treated with drug combinations that are rapidly administered (into the giving-set tube or by i.v. infusion lasting less than 60 minutes) seem to benefit from scalp hypothermia. The fact that good results were obtained with those drugs (adriamycin, cyclophosphamide, 5-fluorouracil, methotrexate, vincristine) and modes of administration that are most commonly used in women with breast cancer or ovarian cancer makes this procedure extremely interesting.

Alopecia↗
PubMed1982

Chemotherapy of carcinomas of the digestive tract.

Adjuvant chemotherapy trials in gastric and colorectal carcinomas are reviewed and no clear benefit from such treatment could be observed. To improve existing chemotherapy regimens, several pilot studies were performed in 95 gastric cancer and 85 colorectal carcinomas patients. Response rate for gastric carcinomas using the mitomycin C plus adriamycin plus 5-fluorouracil (5-FU) (FAM) regimen was 40% and was not improved by the addition of nitrosoureas. In colorectal carcinomas none of the combinations used gave better results than 5-FU alone. Fourteen patients with esophageal carcinoma were treated with combination CDDP and the response rate was as high as 50%.

Antineoplastic Agents↗
PubMed1981

[Current advances in cancer immunotherapy (author's therapy)].

Immunotherapy is still considered as an important therapeutic method in oncology. Experimental basis do exist which support the individualization of several distinct conditions of immunomodulation, some of them being associated with a therapeutic benefit. Numerous immunomodulation molecules or derivatives are now available for clinical investigations. However, effects of immunomodulators on the immune systems which depend on several unknown factors are actually not always fairly correlated with antitumoral treatment. The authors review here the available data obtained from recent clinical studies in man. They attempt to establish the limits of immunotherapy as well as its future possibilities.

BCG Vaccine↗
PubMed1977

[Cutaneous manifestations of angio-immunoblastic lymphadenopathy].

The authors report four cases of angio-immunoblastic lymphadenopathy, presenting with cutaneous lesions: these have a tumoral presentation in two cases while in the other two, the polymorphic aspect of the cutaneous lesions is reminiscent of a toxidermic eruption. In contrast to the relative clinical polymorphism, the pathological findings are monomorphic, i.e., in all cases, there was a vascular proliferation together with a more or less dense cellular infiltrate consisting of cells indistinguishable from those involving the abnormal lymph nodes.

Female↗
PubMedDate not supplied

[Desire for a child after breast cancer].

In France 10% of the new cases of breast carcinomas (more than 25,000) are less than 40 years old; we don't know exactly what is the opinion of these women about having children after such a diagnosis; medical adjuvant treatments, Gn Rh agonists and Tamoxifen or adjuvant chemotherapy can modulate temporarily or definitively fertility. Data on pregnancy in breast cancer survivors are limited and consist only of retrospective series: the prognosis doesn't seem to be influenced by subsequent pregnancy; in practice, when the risk of relapse is high (patients N+ or N- grade III) it's reasonable to wait for two or three years before pregnancy, and when the risk is quite low (microinvasive or T1 low grade N- tumor) no delay between carcinoma's treatment and pregnancy is necessary to preserve the good prognosis.

Adult↗